Merck KGaA (ETR:MRK)
115.40
-8.45 (-6.82%)
May 15, 2025, 5:41 PM CET
Merck KGaA Revenue
Merck KGaA had revenue of 5.28B EUR in the quarter ending March 31, 2025, with 3.13% growth. This brings the company's revenue in the last twelve months to 21.32B, up 2.38% year-over-year. In the year 2024, Merck KGaA had annual revenue of 21.16B with 0.78% growth.
Revenue (ttm)
21.32B
Revenue Growth
+2.38%
P/S Ratio
2.55
Revenue / Employee
358.45K
Employees
59,020
Market Cap
53.85B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21.16B | 163.00M | 0.78% |
Dec 31, 2023 | 20.99B | -1.24B | -5.57% |
Dec 31, 2022 | 22.23B | 2.55B | 12.93% |
Dec 31, 2021 | 19.69B | 2.15B | 12.28% |
Dec 31, 2020 | 17.53B | 1.38B | 8.56% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Fresenius SE & Co. KGaA | 22.13B |
Bayer Aktiengesellschaft | 46.61B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.33B |
SCHOTT Pharma AG & Co. KGaA | 954.68M |
Merck KGaA News
- 7 hours ago - Merck KGaA Non-GAAP EPS of €2.12, revenue of €5.28B; updates FY25 outlook - Seeking Alpha
- 11 hours ago - Merck KGaA Cuts Outlook Amid Macroeconomic Challenges - WSJ
- 11 hours ago - Merck KGaA strikes more cautious tone on 2025 adj profit - Reuters
- 1 day ago - Germany's Merck drops China surcharge on orders after US-China tariff deal - Reuters
- 15 days ago - SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO - Seeking Alpha
- 16 days ago - SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating SpringWorks Therapeutics, Inc. Buyout - Wallstreet:Online
- 17 days ago - SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders - Wallstreet:Online
- 17 days ago - Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B - Investopedia